Ann: Compelling Preclinical Breast Cancer Results, page-98

Well, this is exactly the kind of information that I like to walk out of work with. Forgive me for being late to the party with some commentary on this announcement; I have a sore head from some birthday celebrations.

Dr. T has discussed the important points of the announcement and that is great, but what hasn't been discussed yet is likely the most significant part of this finding.

Looking at papers released around certain cell lines, we can find more amazing data.

There are two studies that have linked FTO overexpression with the MCF-7 breast cancer cells (1,2).

*HCC1937 means normal breast cancer cells.


Also, the studies suggest that FTO knockdown significantly inhibited breast cancer growth, colony formation, and survival




Also, that FTO inhibition can decrease breast cancer cells energy production.



Could this be an indication that the efficacy bisantrene in resistant MCF-7 breast cancer cell lines is due to the recent discovery as a potent FTO inhibitor?

It is my belief that the efficacy we have seen in these cell lines is the first preclinical data we have of bisantrene inhibiting FTO in breast cancer cell lines known to overexpress FTO relative to normal breast cells. I cannot stress enough the importance of this finding. I believe that these findings suggest that bisantrene was inhibiting FTO in these cell lines leading to increased cell death as well as reducing energy production, which in turn decreased tumor growth, metastasis, and colony formation.

Make up your own mind.

All IMO - DYOR.

1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6437932/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452952/